Home/Pipeline/XTS001

XTS001

Alzheimer's Disease

PreclinicalActive

Key Facts

Indication

Alzheimer's Disease

Phase

Preclinical

Status

Active

Company

X-tosis

About X-tosis

X-tosis is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is pioneering a novel therapeutic approach targeting mitochondrial dysfunction via modulation of the VDAC1 protein, a mechanism implicated in over 18 neurological and systemic disorders. Its lead program, XTS001, has demonstrated compelling preclinical efficacy in Alzheimer's models, showing improvements in learning, memory, neuronal survival, and reduction of key pathologies. X-tosis is positioning itself as a platform company with a potentially disease-modifying treatment for a high-unmet-need market.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Amyotrophic Lateral Sclerosis (ALS)Neurodegeneration

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active